David A. Siegel Contrafect Corp Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.09 - $0.19 $1,359 - $2,869	-15,100 Reduced 14.8%	86,900 $8,000
Q3 2022 Nov 14, 2022	BUY	$0.18 - $3.51 $16,002 - $312,039	88,900 Added 678.63%	102,000 $17,000
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $1,953 - $3,115	-700 Reduced 5.07%	13,100 $40,000
Q1 2022 May 16, 2022	SELL	$2.26 - $3.84 $4,971 - $8,448	-2,200 Reduced 13.75%	13,800 $50,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $7,163 - $12,005	-2,900 Reduced 15.34%	16,000 $42,000
Q3 2021 Nov 15, 2021	SELL	$3.19 - $4.43 $30,624 - $42,528	-9,600 Reduced 33.68%	18,900 $77,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $19,690 - $26,950	5,500 Added 23.91%	28,500 $125,000
Q1 2021 May 17, 2021	SELL	$4.46 - $6.68 $34,342 - $51,436	-7,700 Reduced 25.08%	23,000 $110,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $6.4 $6,565 - $8,320	-1,300 Reduced 4.06%	30,700 $155,000
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $4,545 - $6,291	900 Added 2.89%	32,000 $169,000
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $145,859 - $242,891	31,100 New	31,100 $199,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.